- Global Pharma News & Resources

Sebacia Highlights Oral Presentation of EU Real-World Pre-Conditioning Study Results at ASDS Annual Meeting 2018

Sebacia Highlights Oral Presentation of EU Real-World Pre-Conditioning Study Results at ASDS Annual Meeting 2018 Leading Dermatologist Ashish Bhatia, MD to present the interim results on Thursday, October 11

PR Newswire

DULUTH, Ga., Oct. 8, 2018

DULUTH, Ga., Oct. 8, 2018 /PRNewswire/ -- Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that results from its real-world pre-conditioning study in Europe evaluating Sebacia Microparticles for treatment of facial acne has been accepted for an oral presentation during the American Society for Dermatologic Surgery (ASDS) 2018 Annual Meeting, being held October 11-14 in Phoenix, AZ.

The abstract, OA145 "Acne Treatment with Pre-Conditioning and Selective Photothermolysis of Sebaceous Follicles with Gold Microparticles and Laser" will outline results through six months from the multi-center, post-market registry trial at commercial centers in Europe that evaluates the impact of a short skin pre-conditioning period to prepare the skin prior to treatment with Sebacia Microparticles. Dr. Ashish Bhatia, MD, dermatologist, internationally recognized expert in dermatologic surgery and cosmetic surgery, and Associate Professor of Clinical Dermatology at Northwestern University, Feinberg School of Medicine in Chicago, IL, will present the findings on Thursday, October 11th from 4:42 – 4:47 p.m. MST.

FDA-cleared Sebacia Microparticles selectively targets the sebaceous (oil-producing) glands, offering dermatologists a truly innovative approach to acne therapy. In the U.S., Sebacia Microparticles was recently cleared by the U.S. Food and Drug Administration (FDA) for use as an accessory to 1064 nm lasers to facilitate photothermal heating of sebaceous glands for the treatment of mild to moderate inflammatory acne vulgaris. In the EU, Sebacia Microparticles is CE marked and sold in select markets.   

Anthony Lando, Chief Executive Officer, said, "The real-world EU pre-conditioning study represents our commitment to acne sufferers by evaluating the advantages of a short topical pre-conditioning treatment to further improve the clinical results of Sebacia Microparticles for the treatment of acne, while helping patients potentially avoid progression to second- and third-line treatments. We look forward to Dr. Bhatia's presentation on the podium at ASDS and sharing these important interim results with the dermatology community."   

About Sebacia
Sebacia, Inc. is a private medical device and aesthetics company focused on creating advanced topical therapies for the treatment of dermatological conditions, with a primary focus on a novel procedure-based acne treatment. Sebacia's goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne. Sebacia's patented microparticles technology was invented at Rice University, and the proprietary dermatology applications were further developed with researchers from the Wellman Center of Photomedicine at Massachusetts General Hospital. Sebacia Microparticles is cleared for use in the U.S. and in the EU, the two largest dermatology markets in the world. Investors in the company include Accuitive Medical Ventures, Domain Associates, Partners Innovation Fund, Salem Partners and Versant Ventures.

Sebacia, Inc. is located in Atlanta, Georgia. More information is available at or follow us at and


View original content:

SOURCE Sebacia, Inc.

Editor Details

Last Updated: 08-Oct-2018